CALL FOR IDEAS
SU2C-Farrah Fawcett Foundation Human Papillomavirus (HPV) Translational Research Team Grant
The American Association for Cancer Research (AACR), on behalf of Stand Up To Cancer (SU2C) and The Farrah Fawcett Foundation, calls upon members of the cancer community to contribute their ideas to the groundbreaking SU2C-Farrah Fawcett Foundation Human Papillomavirus (HPV) Translational Research Team Grant.
We invite submission of ideas for a multidisciplinary translational cancer research project that addresses critical problems in HPV-related cancers and that can deliver near-term patient benefit through investigation by a Team of two expert investigators. The selected grant will include a translational component, and have the potential for a significant impact for patients with HPV-related cancers. The proposal should include clear plans indicating how the work will be translated into the clinic and deliver near-term benefits to patients with HPV-related cancers. Examples of research areas of interest may include: new promising treatment modalities; molecular mechanisms by which HPV causes cancer to develop and metastasize; development of a new generation of targeted treatments; or, improved or novel methods of either diagnosing HPV-related cancers or monitoring the effects of treatment.
This grant will provide $1 million over three years. The Team may be either inter- or intra-institutional, and both scientists on the Team must hold tenure-track academic appointments. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care. The collective ideas for Team translational research projects suggested by the cancer community will assist the SU2C-Farrah Fawcett Foundation Joint Scientific Advisory Committee (JSAC) in selecting the most promising ideas to be submitted as full research proposals. The Committee will select a SU2C-Farrah Fawcett Foundation Human Papillomavirus (HPV) Translational Research Team Grant from the invited proposals.
SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant
The AACR, on behalf of Stand Up To Cancer (SU2C) and the Lustgarten Foundation, and the Fox Family Foundation, calls upon members of the cancer community to contribute their ideas to the groundbreaking SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant.
We invite submission of ideas for a translational cancer research project that addresses critical problems in pancreatic cancer patient care through convergence research. Convergence represents a broad rethinking of scientific research in order to capitalize on a range of knowledge bases including microbiology, computer science, engineering design, nanotechnology, and other fields. The project should include therapeutic interventions for pancreatic cancer, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators. The project must be designed to accelerate the application of therapeutic agents to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant) and include research brings together biology (e.g. genomics, epigenetics, proteomics, and/or other biological fields) and at least one additional field of research such as physics, engineering, or immunology. Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care.
Letters of Intent will be reviewed by the SU2C-Lustgarten Joint Scientific Advisory Committee (JSAC), and Teams with the most promising idea submissions will be invited to submit full proposals. The JSAC will select a SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team from the invited proposals. The SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team will be awarded up to $8 million over the three-year term of the grant.
Since its launch in 2008, Stand Up To Cancer (SU2C) has funded a total of ten Dream Teams, one International Translational Cancer Research Team and 26 Innovative Research Grants, totaling more than $160 million. These grants encompass more than 550 scientists from 101 institutions conducting more than 40 clinical trials.
On May 28, 2009, one year after its launch, SU2C announced funding of five multi-institutional, cross-disciplinary, three-year “Dream Team” grants, totaling $73.6 million. Since then, SU2C has partnered with other renowned organizations to jointly fund Dream Teams focusing on specific areas of cancer research. In December 2011, SU2C and the Melanoma Research Alliance announced a new Dream Team that will receive $6 million over three years for translational research focusing on melanoma. In 2012, three new Dream Teams were announced focusing on prostate cancer (two Dream Teams in collaboration with the Prostate Cancer Foundation), and cancer immunology (one Dream Team in collaboration with the Cancer Research Institute). Each jointly funded grant will provide $10 million over three years for a total of $30 million. In April 2013, SU2C and the St. Baldrick's Foundation announced a new Dream Team that will receive $14.5 million over four years for translational research focusing on pediatric cancer.
In addition, on August 2, 2012, SU2C, in collaboration with Kankerbestrijding/The Dutch Cancer Society (KWF), announced recipients of a new Sta Op Tegen Kanker International Translational Cancer Research Grant. This grant provides funding of €1.2 million ($1.3 million U.S.) for four years. The funding mechanism represents a new, focused effort to affect advances in cancer research as rapidly as possible through the creation of collaborative, international translational cancer research “Team.”
Finally, through its Innovative Research Grants, SU2C has made an effort to support the next generation of extraordinary leaders in their quest to conquer cancer. These grants provide up to $750,000, over a three-year term, to early-career scientists whose novel, high-risk, high-reward research proposals may have significant potential for translational application. Thirteen grants were awarded in 2009, and 13 more in 2011 totaling $19.4 million.
Updated: Dec. 4, 2013